Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Ottmann

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Blood Cancer Journal|September 8, 2018
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinibOliver Ottmann, Giuseppe Saglio, Jane F Apperley, et al.
Haematologica|October 21, 2017
Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trialsRichard F Schlenk, Jürgen Krauter, Emmanuel Raffoux, et al.
Blood|December 23, 2006
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisJorge Cortes, Philippe Rousselot, Dong-Wook Kim, et al.
Blood|February 2, 2024
Management of ALL in adults: 2024 ELN recommendations from a European expert panelNicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, et al.
Blood|January 31, 2024
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panelNicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromesFelicitas Thol, Inna Friesen, Frederik Damm, et al.
Annals of Hematology|March 24, 2017
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemiaAnna Both, Jürgen Krauter, Frederik Damm, et al.
Blood|March 6, 2012
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesFelicitas Thol, Sofia Kade, Carola Schlarmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemiaFrederik Damm, Michael Heuser, Michael Morgan, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Blood Cancer Journal|September 8, 2018
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinibOliver Ottmann, Giuseppe Saglio, Jane F Apperley, et al.
Haematologica|October 21, 2017
Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trialsRichard F Schlenk, Jürgen Krauter, Emmanuel Raffoux, et al.
Blood|December 23, 2006
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisisJorge Cortes, Philippe Rousselot, Dong-Wook Kim, et al.
Blood|February 2, 2024
Management of ALL in adults: 2024 ELN recommendations from a European expert panelNicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, et al.
Blood|January 31, 2024
Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panelNicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromesFelicitas Thol, Inna Friesen, Frederik Damm, et al.
Annals of Hematology|March 24, 2017
The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemiaAnna Both, Jürgen Krauter, Frederik Damm, et al.
Blood|March 6, 2012
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesFelicitas Thol, Sofia Kade, Carola Schlarmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemiaFrederik Damm, Michael Heuser, Michael Morgan, et al.
Leukemia|December 18, 2018
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeJorge E Cortes, Florian H Heidel, Andrzej Hellmann, et al.
Pageof 6